---
layout: default
title: Avelumab
parent: 僅模型預測 (L5)
nav_order: 38
evidence_level: L5
indication_count: 10
---

# Avelumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Avelumab: Evaluation Report — Insufficient Data for Full Repurposing Analysis

## One-Sentence Summary

Avelumab (DrugBank: DB11945) is a fully human anti-PD-L1 monoclonal antibody checkpoint inhibitor currently not approved in Taiwan.
This Evidence Pack contains **no TxGNN predicted indications**, and critical data fields — including original indication, mechanism of action, and safety profile — are absent.
A **Hold** decision is recommended until the data gaps identified below are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies retrievable |
| Taiwan Market Status | ✗ Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, this section cannot be completed. The Evidence Pack does not include original indication data (`original_indications: []`) or mechanism of action information (`original_moa: [Data Gap]`), and the `predicted_indications` array is empty.

DrugBank query (Query Log ID 3) confirmed one record exists for Avelumab in DrugBank, but the parsed content was not forwarded into the Evidence Pack. Retrieving the full DrugBank entry — including pharmacology, targets, and categories — is a prerequisite before any mechanistic rationale can be constructed.

---

## Clinical Trial Evidence

Currently no predicted indication is available to associate clinical trials with. Clinical trial evidence retrieval is deferred pending TxGNN prediction output.

---

## Literature Evidence

Currently no predicted indication is available to associate literature with. Literature retrieval is deferred pending TxGNN prediction output.

---

## Taiwan Market Information

Avelumab has **no approved authorizations** in Taiwan. The TFDA query (Query Log ID 1) returned zero results.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: TFDA package insert query (Query Log ID 4) returned 1 result, indicating a package insert document may exist. The parsed safety content — warnings, contraindications, and drug interactions — was not populated into this Evidence Pack. Drug interaction query (Query Log ID 2) returned no results.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is structurally incomplete — no predicted indications, no original indication records, no MOA, and no safety data are present. A repurposing evaluation cannot be performed without these inputs.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Parse TFDA package insert PDF to extract contraindications and key warnings; this is required before any safety screening (S1 gate)
- **[High — DG002]** Retrieve full Avelumab entry from DrugBank API to populate mechanism of action, pharmacological targets, and drug categories
- **[Required]** Run TxGNN prediction pipeline for Avelumab (DB11945) to generate `predicted_indications` with disease scores, clinical trial links, and literature references
- **[Required]** Confirm original approved indication(s) from DrugBank or TFDA package insert to anchor the repurposing comparison
- **[Recommended]** After MOA is confirmed, verify whether Avelumab meets antineoplastic/cytotoxic criteria to determine if a Cytotoxicity section is required in the final report
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

